CN104803925A - 2,4,5-trisubstituted pyrimidine compounds taking FGFRs (fibroblast growth factor receptors) as targets as well as preparation methods and application of 2,4,5-trisubstituted pyrimidine compounds - Google Patents
2,4,5-trisubstituted pyrimidine compounds taking FGFRs (fibroblast growth factor receptors) as targets as well as preparation methods and application of 2,4,5-trisubstituted pyrimidine compounds Download PDFInfo
- Publication number
- CN104803925A CN104803925A CN201510180883.3A CN201510180883A CN104803925A CN 104803925 A CN104803925 A CN 104803925A CN 201510180883 A CN201510180883 A CN 201510180883A CN 104803925 A CN104803925 A CN 104803925A
- Authority
- CN
- China
- Prior art keywords
- pyrimidine
- chloro
- take
- ammonia
- fgfr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091008794 FGF receptors Proteins 0.000 title claims abstract description 35
- -1 2,4,5-trisubstituted pyrimidine compounds Chemical class 0.000 title claims abstract description 23
- 238000002360 preparation method Methods 0.000 title abstract description 8
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 title abstract 5
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims abstract description 30
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 4
- 229940041181 antineoplastic drug Drugs 0.000 claims abstract description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 36
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 20
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 claims description 20
- 238000006243 chemical reaction Methods 0.000 claims description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 16
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- 239000000126 substance Substances 0.000 claims description 9
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 claims description 8
- OFCBNMYNAHUDGE-UHFFFAOYSA-N 2-chloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1 OFCBNMYNAHUDGE-UHFFFAOYSA-N 0.000 claims description 8
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 claims description 8
- 239000007787 solid Substances 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 8
- 238000000605 extraction Methods 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 150000003230 pyrimidines Chemical class 0.000 claims description 6
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 6
- ZCHPKWUIAASXPV-UHFFFAOYSA-N acetic acid;methanol Chemical group OC.CC(O)=O ZCHPKWUIAASXPV-UHFFFAOYSA-N 0.000 claims description 5
- 239000003480 eluent Substances 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 5
- 238000006386 neutralization reaction Methods 0.000 claims description 4
- 238000010898 silica gel chromatography Methods 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 229920006395 saturated elastomer Polymers 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 235000002639 sodium chloride Nutrition 0.000 claims description 3
- 238000000967 suction filtration Methods 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000010408 film Substances 0.000 claims description 2
- 238000009472 formulation Methods 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 229940124531 pharmaceutical excipient Drugs 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 238000013268 sustained release Methods 0.000 claims description 2
- 239000012730 sustained-release form Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000035484 reaction time Effects 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 18
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract description 13
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract description 13
- 210000004027 cell Anatomy 0.000 abstract description 10
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 abstract description 7
- 206010028980 Neoplasm Diseases 0.000 abstract description 7
- 201000011510 cancer Diseases 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 5
- 230000026731 phosphorylation Effects 0.000 abstract description 4
- 238000006366 phosphorylation reaction Methods 0.000 abstract description 4
- 102000001253 Protein Kinase Human genes 0.000 abstract description 3
- 230000000259 anti-tumor effect Effects 0.000 abstract description 3
- 108060006633 protein kinase Proteins 0.000 abstract description 3
- 230000001028 anti-proliverative effect Effects 0.000 abstract description 2
- 230000001419 dependent effect Effects 0.000 abstract description 2
- 206010067484 Adverse reaction Diseases 0.000 abstract 1
- 230000006838 adverse reaction Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 210000004881 tumor cell Anatomy 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 98
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 54
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 31
- 238000005481 NMR spectroscopy Methods 0.000 description 26
- 238000005259 measurement Methods 0.000 description 25
- 239000000843 powder Substances 0.000 description 25
- 125000003118 aryl group Chemical group 0.000 description 24
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 24
- 150000001412 amines Chemical class 0.000 description 18
- 230000000694 effects Effects 0.000 description 9
- 108091000080 Phosphotransferase Proteins 0.000 description 8
- 102000020233 phosphotransferase Human genes 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- YAAWASYJIRZXSZ-UHFFFAOYSA-N pyrimidine-2,4-diamine Chemical class NC1=CC=NC(N)=N1 YAAWASYJIRZXSZ-UHFFFAOYSA-N 0.000 description 6
- 239000000919 ceramic Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 3
- 108010087230 Sincalide Proteins 0.000 description 3
- 125000003368 amide group Chemical group 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 229940125829 fibroblast growth factor receptor inhibitor Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- QADPYRIHXKWUSV-UHFFFAOYSA-N BGJ-398 Chemical compound C1CN(CC)CCN1C(C=C1)=CC=C1NC1=CC(N(C)C(=O)NC=2C(=C(OC)C=C(OC)C=2Cl)Cl)=NC=N1 QADPYRIHXKWUSV-UHFFFAOYSA-N 0.000 description 2
- 206010005003 Bladder cancer Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- YLXYSOAZRMBYBK-UHFFFAOYSA-N CN1CCNCC1.NC1=CC=CC=C1 Chemical compound CN1CCNCC1.NC1=CC=CC=C1 YLXYSOAZRMBYBK-UHFFFAOYSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 229940125904 compound 1 Drugs 0.000 description 2
- 230000002508 compound effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000001275 rectum cancer Diseases 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 201000000498 stomach carcinoma Diseases 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 201000005112 urinary bladder cancer Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- WQDDXVGJRSTLED-UHFFFAOYSA-N 1-methyl-4-phenylpiperazine Chemical compound C1CN(C)CCN1C1=CC=CC=C1 WQDDXVGJRSTLED-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- NHFDRBXTEDBWCZ-ZROIWOOFSA-N 3-[2,4-dimethyl-5-[(z)-(2-oxo-1h-indol-3-ylidene)methyl]-1h-pyrrol-3-yl]propanoic acid Chemical compound OC(=O)CCC1=C(C)NC(\C=C/2C3=CC=CC=C3NC\2=O)=C1C NHFDRBXTEDBWCZ-ZROIWOOFSA-N 0.000 description 1
- XXJWYDDUDKYVKI-UHFFFAOYSA-N 4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxy-7-[3-(1-pyrrolidinyl)propoxy]quinazoline Chemical compound COC1=CC2=C(OC=3C(=C4C=C(C)NC4=CC=3)F)N=CN=C2C=C1OCCCN1CCCC1 XXJWYDDUDKYVKI-UHFFFAOYSA-N 0.000 description 1
- 0 CCN(CC1)CCN1c(cc1)ccc1Nc1ncnc(N(C)C(Nc(c(Cl)c(*C)cc2*C)c2Cl)=*)c1 Chemical compound CCN(CC1)CCN1c(cc1)ccc1Nc1ncnc(N(C)C(Nc(c(Cl)c(*C)cc2*C)c2Cl)=*)c1 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 description 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 description 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- LTEJRLHKIYCEOX-PUODRLBUSA-N [(2r)-1-[4-[(4-fluoro-2-methyl-1h-indol-5-yl)oxy]-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl]oxypropan-2-yl] 2-aminopropanoate Chemical compound C1=C2NC(C)=CC2=C(F)C(OC2=NC=NN3C=C(C(=C32)C)OC[C@@H](C)OC(=O)C(C)N)=C1 LTEJRLHKIYCEOX-PUODRLBUSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960002412 cediranib Drugs 0.000 description 1
- PIQCTGMSNWUMAF-UHFFFAOYSA-N chembl522892 Chemical compound C1CN(C)CCN1C1=CC=C(NC(=N2)C=3C(NC4=CC=CC(F)=C4C=3N)=O)C2=C1 PIQCTGMSNWUMAF-UHFFFAOYSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000012447 hatching Effects 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- WOSKHXYHFSIKNG-UHFFFAOYSA-N lenvatinib Chemical compound C=12C=C(C(N)=O)C(OC)=CC2=NC=CC=1OC(C=C1Cl)=CC=C1NC(=O)NC1CC1 WOSKHXYHFSIKNG-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- WJEOLQLKVOPQFV-UHFFFAOYSA-N masitinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3SC=C(N=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 WJEOLQLKVOPQFV-UHFFFAOYSA-N 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- XZXHXSATPCNXJR-ZIADKAODSA-N nintedanib Chemical compound O=C1NC2=CC(C(=O)OC)=CC=C2\C1=C(C=1C=CC=CC=1)\NC(C=C1)=CC=C1N(C)C(=O)CN1CCN(C)CC1 XZXHXSATPCNXJR-ZIADKAODSA-N 0.000 description 1
- 229960004378 nintedanib Drugs 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- PHXJVRSECIGDHY-UHFFFAOYSA-N ponatinib Chemical compound C1CN(C)CCN1CC(C(=C1)C(F)(F)F)=CC=C1NC(=O)C1=CC=C(C)C(C#CC=2N3N=CC=CC3=NC=2)=C1 PHXJVRSECIGDHY-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000002476 tumorcidal effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/50—Three nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/48—Two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
The invention belongs to the field of medicinal chemistry and particularly relates to 2,4,5-trisubstituted pyrimidine compounds taking FGFRs (fibroblast growth factor receptors) as targets as well as preparation methods and an application of the 2,4,5-trisubstituted pyrimidine compounds. The compounds can selectively inhibit phosphorylation of FGFR kinase so as to be used for treating malignant tumors closely related with the kinase, and can reduce adverse reactions; the compounds can be used for treating tumors related with the FGFR kinase or relevant diseases. The general formula of the 2,4,5-trisubstituted pyrimidine compounds is shown in the specification, wherein R<1>, R<2> and R<3> can be selected from multiple substituents and can be combined randomly. The 2,4,5-trisubstituted pyrimidine compounds taking the FGFRs as the targets have a good inhibition function on the FGFR1 kinase, have an anti-proliferation function on FGFR1-dependent tumor cell line KG1 cells, can be used for preparing antitumor drugs and have better antitumor effects.
Description
Technical field
The invention belongs to medicinal chemistry art, being specifically related to a class take FGFR as 2,4,5-trisubstituted pyrimidine compounds of target spot and its production and use.
Background technology
In this field of protein kinase, fibroblast growth factor acceptor FGFR family is that a target spot had a great attraction is in oncotherapy.The FGFR family of receptor tyrosine kinase comprises four members, is FGFR1, FGFR2, FGFR3 and FGFR4 respectively.They have highly similar sequence homology.The kinase whose imbalance of FGFR and Several Kinds of Malignancy closely related, as kinds cancers such as mammary cancer, bladder cancer, cancer of the stomach, prostate cancer, the rectum cancer, therefore medical oncology is constantly to its research and Diagnosis and Treat to cancer.
Suppress the protein kinase with disease-related, block and tumoricidal signal transmission, realize by multiple method, but the antisense oligonucleotide due to synthesis is subject to the attack of ribozyme and degrades, there is security, stability and the problems such as effect of missing the target in RNA perturbation technique, therefore new drug development personnel attempt the chemical small molecule inhibitor screening FGFR from organic synthesis small molecules.Up to now, existing multiple micromolecular inhibitor enters clinical experimental stage, as NVP-BGJ398,
BIBF-1120, TKI-258, BMS-582664, AZD-2171, AB-1010, TSU-68, AP-24534 and E-7080.
The medicine that current research is the fastest is NVP-BGJ398, and it, as the FGFR inhibitor of highly selective, is used for the treatment of solid malignant tumor, is in during the clinical I phase studies.It is the FGFR inhibitor of parent nucleus that market not yet has with pyrimidine, therefore urgently to develop with pyrimidine be the FGFR inhibitor of parent nucleus.
Summary of the invention
An object of the present invention is for solving the problems of the technologies described above, a class is provided to take FGFR as 2 of target spot, 4,5-trisubstituted pyrimidine compounds and its production and use, can reduce untoward reaction while that this compound optionally can suppressing the kinase whose phosphorylation of FGFR thus be used for the treatment of the malignant tumour of kinases close ties therewith; Can be used in treating tumour or relevant disease that FGFR kinases is correlated with.
For realizing above-mentioned technique effect, technical scheme of the present invention is:
One class take FGFR as 2,4,5-trisubstituted pyrimidine compounds of target spot, has following general formula:
Wherein: R
1following arbitrary substituted radical can be selected from:
R
2following arbitrary substituted radical can be selected from:
R
3cl or NO can be selected from
2in any one;
Above R
1, R
2, R
3in substituting group can arbitrary combination.
A kind ofly prepare the method that an above-mentioned class take FGFR as 2,4,5-trisubstituted pyrimidine compounds of target spot, comprise the steps:
Step one: take the chloro-5-nitro-pyrimidine of 2,4-bis-, DIPEA and R
1-NH
2in flask, add methylene chloride under stirring and make it dissolve, room temperature reaction 5h, after completion of the reaction, add saturated aqueous common salt, mixture dichloromethane extraction, concentrated, obtain the pulverous 2-R of red solid
1the chloro-5-nitro-pyrimidine of-ammonia-4-.
Step 2: take described 2-R
1-ammonia-4-chloro-5-nitro-pyrimidine and described R
2-NH
2in flask, add sec-butyl alcohol and make it dissolve under stirring, backflow 2h, after reaction terminates, be cooled to room temperature, add sodium bicarbonate neutralization, be extracted with ethyl acetate 3 times, concentrated, silica gel column chromatography, eluent is acetate-methanol, and the volume ratio of ethyl acetate and methyl alcohol is 20: 1, obtains 2-R
1-ammonia-4-R
2-ammonia-5-R
3pyrimidine.
Wherein, R
3for nitro, R
1and R
2definition identical with above-mentioned definition, multiple substituting group can be had to select.
Further, every 1g 2,4-bis-chloro-5-nitro-pyrimidine methylene dichloride 20ml in described step one; The chloro-5-nitro-pyrimidine of the ratio of amount of substance: 2,4-bis-: DIPEA: R
1-NH
2=1: 1: 1.
Further, 2-R described in every 500mg
1-ammonia-4-chloro-5-nitro-pyrimidine sec-butyl alcohol 15-20ml, then trifluoroacetic acid is instilled in flask, the ratio of amount of substance: 2-R
1the chloro-5-R of-ammonia-4-
3pyrimidine: R
2-NH
2: trifluoroacetic acid is 1: 1: 1.
A kind ofly prepare the method that an above-mentioned class take FGFR as 2,4,5-trisubstituted pyrimidine compounds of target spot, comprise the steps:
Step one: take 2,4,5-trichloropyrimidine, Anhydrous potassium carbonate and described R
1-NH
2in flask, stirring adds DMF makes it dissolve, every 1g 2,4,5-trichloropyrimidine DMF 5-10ml, the ratio of amount of substance: 2,4,5-trichloropyrimidine: Anhydrous potassium carbonate: R
1-NH
2=1: 2: 1,60 DEG C of reaction 2-3h, after completion of the reaction, are cooled to room temperature, add a large amount of frozen water, have solid to separate out, suction filtration, dry, obtain 2-R
1-ammonia-4,5-dichloro pyrimidine;
Step 2: take described 2-R
1-ammonia-4-chloro-5-dichloro pyrimidine and described R
2-NH
2in flask, add described sec-butyl alcohol under stirring and make it dissolve, 2-R described in every 500mg
1-ammonia-4-chloro-5-dichloro pyrimidine sec-butyl alcohol 20-30ml, then trifluoroacetic acid is instilled in flask, the ratio of amount of substance: 2-R
1the chloro-5-dichloro pyrimidine of-ammonia-4-: R
2-NH
2: trifluoroacetic acid=1: 1: 1, backflow 2h.After reaction terminates, be cooled to room temperature, add sodium bicarbonate neutralization, be extracted with ethyl acetate 3 times, concentrated, silica gel column chromatography, eluent is acetate-methanol, and the volume ratio of ethyl acetate and methyl alcohol is 20: 1, obtains 2-R
1-ammonia-4-R
2-ammonia-5-R
3pyrimidine.
R
3for chlorine, R
1and R
2definition identical with above-mentioned definition, multiple substituting group can be had to select.
One class take FGFR as the purposes of 2,4,5-trisubstituted pyrimidine compounds of target spot, and described purposes is the application prepared in antitumor drug.
A kind of pharmaceutical composition, comprises 2,4, the 5-trisubstituted pyrimidine compounds that pharmaceutical excipient and a class take FGFR as target spot.
Be 2 of target spot with FGFR containing a class, 4, the pharmaceutical composition of 5-trisubstituted pyrimidine compounds, the dosage form of described pharmaceutical composition is any one of injection, tablet, capsule, aerosol, suppository, film, pill, ointment, control-released agent, sustained release dosage or nanometer formulation.
Beneficial effect of the present invention comprises: of the present invention is that 2,4,5-trisubstituted pyrimidine compounds of target spot have good restraining effect to FGFR1 kinases and FGFR1 dependent tumors cell strain KG1 cell has antiproliferative effect with FGFR.Can be used for preparing antitumor drug, and antitumous effect is better.
Embodiment
Hereafter will describe the present invention in detail in conjunction with specific embodiments.It should be noted that the combination of technical characteristic or the technical characteristic described in following embodiment should not be considered to isolated, they can mutually be combined thus be reached better technique effect.
Embodiment 1 N-{4-{{2-{ [4-methylpiperazine-1-yl] benzene } amine }-5-nitro-pyrimidine-4-base } benzene } preparation of ethanamide (compound 1)
(1) N-{4-[(the chloro-5-nitro-pyrimidine of 2--4-base) amine] phenyl } preparation of ethanamide
Under the condition of ice bath, by chloro-for 2,4-bis-5-nitro-pyrimidine (5g, 25.7mmol) be dissolved in methylene dichloride (100ml), add DIPEA (4.3ml, 25.7mmol) with acetparaminosalol aniline (3.87g, 25.7mmol).Remove ice bath, reaction mixture at room temperature reacts 5h, then adds saturated aqueous common salt (200ml).Mixture methylene dichloride (300ml) extracts.Organic over anhydrous magnesium sulfate carries out drying, and concentrate to obtain solid, product is not further purified, and obtains 6.34g red solid, yield 90.0%.
(2) N-{4-{{2-{ [4-methylpiperazine-1-yl] benzene } amine }-5-nitro-pyrimidine-4-base } benzene } preparation of ethanamide (compound 1)
Take N-{4-[(the chloro-5-nitro-pyrimidine of 2--4-base) amine] phenyl } ethanamide (1g, 3.25mmol), 4-methylpiperazine aniline (746.0mg, 3.90mmol) with trifluoroacetic acid (0.25ml, 3.25mmol) be dissolved in sec-butyl alcohol (20ml), finish 100 DEG C of reaction 6h.Cooling, concentrating under reduced pressure system, the oily matter obtained is poured in frozen water, add sodium bicarbonate and be neutralized to neutrality, extraction into ethyl acetate, dry, concentrated organic phase obtains crude product, column chromatography (ethyl acetate: methyl alcohol=20: 1) obtain red solid product 2.78g, yield 61.7%.
The chloro-2-{ of embodiment 2 N-{4-{{5-[4-(4-methylpiperazine-1-yl) benzene] amido } pyrimidine-4-yl } amine } phenyl } preparation of ethanamide (compound 2)
(1) N-{4-[(2,5-dichloro pyrimidine-4-base) amine] phenyl } preparation of ethanamide
Take acetparaminosalol aniline (1.31g, 8.72mmol) and be dissolved in DMF (20ml), then add Anhydrous potassium carbonate (2.42g, 17.5mmol) and 2,4,5-trichloropyrimidine (1.0ml, 8.72mmol).Reaction mixture is heated to 60 DEG C of reaction 2h.After completion of the reaction, cool to room temperature, adds a large amount of frozen water, separates out solid, suction filtration, and dry, product is not further purified, and obtains 2.3g, yield 90%.
(2) the chloro-2-{ of N-{4-{{5-[4-(4-methylpiperazine-1-yl) benzene] amido } pyrimidine-4-yl } amine } phenyl } preparation of ethanamide
Take N-{4-[(2,5-dichloro pyrimidine-4-base) amine] phenyl } ethanamide (1.6g, 5.45mmol), 4-methylpiperazine aniline (1.24g, 6.46mmol) with trifluoroacetic acid (0.42ml, 5.45mmol) be dissolved in sec-butyl alcohol (30ml), be heated to 100 DEG C of reaction 6h.Cooling, concentrating under reduced pressure system, the oily matter obtained is poured in frozen water, add sodium bicarbonate and be neutralized to neutrality, extraction into ethyl acetate, dry, concentrated organic phase obtains crude product, column chromatography (ethyl acetate: methyl alcohol=20: 1) obtain white solid product 1.47g, yield 60.3%.
By any one method of embodiment 1 or 2, be raw material with the aniline of 2,4-bis-chloro-5-nitro-pyrimidine or 2,4,5-trichloropyrimidine and different replacement forms, having synthesized listed by table 1 take FGFR as 2,4,5-trisubstituted pyrimidine compounds 1 ~ 26 of target spot.
Be each R group in 2,4,5-trisubstituted pyrimidine compounds of target spot with FGFR in table 1 general formula I
Note: initial feed is all purchased from aladdin company.
Embodiment 3 compound is to the mensuration of FGFR kinase activity
Measure compound to the inhibit activities of FGFR1 by LANCE ULTRA Assay method, and compare with positive control drug, filter out active good compound.FGFR1 is that CARNA company buys.
Concrete grammar: the compound tested, ATP, specific substrate and FGFR1 kinases kinase dilution liquid dilute.Containing FGFR1, ATP, substrate, HEPES (PH=7.5), MgCl in kinase reaction mixture
2, EGTA, Tween-20.Do not add any compound group and do 100% phosphorylation contrast, add EDTA termination reaction group after adding FGFR1 kinases at once and contrast as 0% phosphorylation.After hatching 1h altogether under kinase reaction mixture room temperature, add EDTA termination reaction 5 minutes.Add specific antibody again, continue under room temperature to hatch 1h altogether, detect exciting light with PerkinElmer Envision kinases instrument.Detect gained signal value according to kinases instrument, obtain inhibiting rate or GraphPad calculating test-compound IC with formulae discovery
50value.
Embodiment 4 compound is to the mensuration of KG1 cell inhibitory rate
Compound detects with CCK-8 Cell counting Kit (Dojindo) the inhibited proliferation of KG1 cell.Concrete steps are as follows: the KG1 cell being in logarithmic phase is seeded in 96 well culture plates by proper density, and every hole 90 μ L, after overnight incubation, adds the compound effects 72h of different concns, and setting solvent control group (negative control).After compound effects cell 72h, the impact of compound on intracellular propagation adopts CCK-8 Cell counting Kit (Dojindo) to detect, every hole adds 10 μ L CCK-8 reagent, be placed in after 37 DEG C of incubators place 2-4h, with long orifice plate microplate reader SpectraMax 190 reading that declines of all-wave, mensuration wavelength is 450nm.
Adopt with the inhibiting rate (%) of following formulae discovery compound on tumor Growth of Cells:
Inhibiting rate (%)=(OD control wells-OD dosing holes)/OD control wells × 100%
The test result of the external FGFR1 kinase activity of table 2 part of compounds
The external FGFR1 kinase activity of table 3 part of compounds is to KG1 cytoactive test result
(in table, compound numbers corresponds to compound numbers above)
Pharmacology test result shows, the compounds of this invention 15,16,17,18 has good FGFR1 inhibit activities, and there is good Anti-tumor angiogenesis, can be used for the clinical disease prevented or treatment is relevant with fibroblast growth factor acceptor kinases 1 inhibitor, these diseases can be: the kinds cancers such as mammary cancer, bladder cancer, cancer of the stomach, prostate cancer, the rectum cancer.
Measure compound numbers be 1 ~ 26 proterties, productive rate, fusing point, hydrogen modal data and mass spectrum:
Embodiment 5 N-{4-{{2-{ [4-methylpiperazine-1-yl] benzene } amine }-5-nitro-pyrimidine-4-base } benzene } measurement result of ethanamide (1) is:
Red powder; Productive rate 61.7%; M.p:269.5-270.4 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.251 (1H, s ,-NH), 10.206 (1H, s ,-NH), 10.119 (1H, s ,-NH), 8.998 (1H, s, H-6), 7.594 (2H, d, J=8.4Hz, H-3 ", H-5 "), 7.4 00 (2H, d, J=8.4Hz, H-3 ', H-5 '), 7.326 (2H, d, J=9.0Hz, H-2 "; H-6 "), 6.712 (2H, d, J=9.0Hz, H-2 ', H-6 '), 3.093 (4H, s ,-CH
2n (aryl) CH
2-), 2.591 (4H, s ,-CH
2n (CH
3) CH
2-), 2.317 (3H, s ,-NCH
3), 2.063 (3H, s ,-NHCOCH
3).
13c NMR (600MHz, DMSO-d6): δ (ppm) 168.77,159.18,157.73,155.08,147.33,137.25,132.37,130.52,126.12 × 2,121.94 × 2,119.50 × 2,115.48 × 2,54.43 × 2,48.01 × 2,45.26,24.12.ESI-MS m/z:463.1 (M+H)
+.
Embodiment 6 N
2-[4-(4-methylpiperazine-1-yl) benzene]-N
4-(4-morpholine benzene)-5-nitro-pyrimidine-2,4-diamines (2) measurement result is:
Red powder; Productive rate 65.4%; M.p:253.4-255.6 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.184 (1H, s ,-NH), 10.168 (1H, s ,-NH), 8.991 (1H, s, H-6), 7.335 (2H, d, J=8.4Hz, H-2 ', H-6 '), 7.312 (2H, d, J=8.4Hz, H-2 ", H-6 "), 6.974 (2H, d, J=8.4Hz, H-2 ', H-6 '), 6.702 (2H, d, J=8.4Hz, H-3 ", H-5 "), (3.128 8H, s, morpholine), 3.098 (3H, s ,-NCH
3), 2.610 (4H, s ,-CH
2n (aryl) CH
2-), 2.335 (4H, s ,-CH
2n (CH
3) CH
2-) .ESI-MS m/z:491.1 (M+H)
+.
Embodiment 7 N
2the measurement result of-[4-(4-methylpiperazine-1-yl) benzene]-5-nitro-N4-[3-(trifluoromethyl) benzene] pyrimidine-2,4-diamines (3) is:
Red powder; Productive rate 71.2%; M.p:219.3-220.7 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.463 (1H, s ,-NH), 10.303 (1H, s ,-NH), 9.047 (1H, s, H-6), 7.914 (1H, s, H-2 "), 7.823 (1H, d, J=6.6Hz; H-6 "), 7.619 (1H, t, J=7.2Hz, H-5 "), 7.613 (1H, t, J=7.2Hz; H-4 "), 7.299 (2H, d, J=9.0Hz, H-3 ', H-5 '), 6.699 (2H, d, J=9.0Hz, H-2 ', H-6 '), 3.029 (4H, s ,-CH
2n (aryl) CH
2-), 2.425 (4H, s ,-CH
2n (CH
3) CH
2-), 2.195 (3H, s ,-NCH
3) .ESI-MS m/z:474.2 (M+H)
+.
Embodiment 8 N
4the measurement result of-(9H-fluorenes-2-base)-N2-[4-(4-methylpiperazine-1-yl) benzene]-5-nitro-pyrimidine-2,4-diamines (4) is:
Brown ceramic powder, productive rate 66.7%, m.p:248.9-250.4 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.487 (1H, s,-NH), 10.322 (1H, s,-NH), 9.066 (1H, s, H-6), 7.955 (2H, d, J=7.8Hz, H-7 ", H-8 "), 7.850 (1H, s, H-2 "), 7.646 (1H, d, J=7.2Hz, H-4 "), 7.476 (1H, d, J=8.4Hz, H-9 "), 7.434 (1H, t, J=7.8Hz, H-6 "), 7.354 (1H, t, J=7.8Hz, H-5 "), 7.341 (2H, d, J=8.4Hz, H-3 ', H-5 '), 6.590 (2H, d, J=8.4Hz, H-2 ', H-6 '), 3.886 (2H, s,-CH
2-), 3.443 (4H, s ,-CH
2n (aryl) CH
2-), 2.793 (4H, s ,-CH
2n (CH
3) CH
2-), 2.515 (3H, s ,-NCH
3) .ESI-MS m/z:494.1 (M+H)
+.
Embodiment 9 N
4-(3-bromophenyl)-N
2the measurement result of-[4-(4-methylpiperazine-1-yl) phenyl]-5-nitro-pyrimidine-2,4-diamines (5) is:
Red powder; Productive rate 69.8%; M.p:222.1-224.5 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.377 (1H, s ,-NH), 10.319 (1H, s ,-NH), 9.036 (1H, s, H-6), 7.877 (1H, s, H-2 '), 7.482 (1H, d, J=7.2Hz, H-6 "), 7.430 (1H, d, J=7.8Hz; H-4 "), 7.369 (2H, d, J=7.8Hz, H-3 ', H-5 '), 7.335 (1H, t, J=7.8Hz, H-5 "), 6.816 (2H, d; J=9.0Hz, H-2 ', H-6 '); 3.098 (4H, s ,-CH
2n (aryl) CH
2-), 2.547 (4H, s ,-CH
2n (CH
3) CH
2-), 2.281 (3H, s ,-NCH
3) .ESI-MS m/z:474.9 (M+H)
+.
Embodiment 10 N
4the measurement result of-(1H-indoles-5-base)-N2-[4-(4-methylpiperazine-1-yl) benzene]-5-nitro-pyrimidine-2,4-diamines (6) is:
Yellow powder, productive rate 65.9%, m.p 269.8-271.5 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 11.288 (1H, s, H-1 "), 10.362 (1H, s,-NH), 10.248 (1H, s,-NH), 9.041 (1H, s, H-6), 7.740 (1H, s, H-4 "), 7.439 (1H, d, J=9.0Hz, H-7 "), 7.370 (1H, d, J=8.4Hz, H-2 "), 7.286 (1H, d, J=9.0Hz, H-6 "), 7.142 (1H, d, J=8.4Hz, H-3 "), 6.555 (2H, d, J=8.4Hz, H-3 ', H-5 '), 6.431 (2H, d, J=8.4Hz, H-2 ', H-6 '), 3.121 (4H, t, J=7.8Hz,-CH
2n (aryl) CH
2-), 3.019 (4H, t, J=12Hz ,-CH
2n (CH
3) CH
2-), 2.791 (3H, s ,-NCH
3) .ESI-MS m/z:445.1 (M+H)
+.
Embodiment 11 N
2the measurement result of-[4-(4-methylpiperazine-1-yl) phenyl]-5-nitro-N4-(tolyl) pyrimidine-2,4-diamines (7) is:
Red powder; Productive rate 70.1%; M.p:218.3-219.8 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.318 (1H, s ,-NH), 10.258 (1H, s ,-NH), 9.021 (1H, s, H-6), 7.443 (1H, d, J=9.6Hz, H-6 "), 7.384 (2H, d; J=8.4Hz, H-3 ', H-5 ') and, 7.297 (1H; d, J=7.2Hz, H-4 "), 7.254 (1H, t, J=7.8Hz, H-5 "), 7.053 (1H; s, H-2 "), 6.760 (2H, d, J=8.4Hz, H-2 ', H-6 '), 3.058 (4H, s ,-CH
2n (aryl) CH
2-), 2.444 (4H, s ,-CH
2n (CH
3) CH
2-), 2.250 (3H, s ,-NCH
3), 2.206 (3H, s ,-CH
3) .13C NMR (600MHz, DMSO-d6): δ (ppm) 159.50,157.90,154.48,147.91,138.34,137.11,130.14,128.77,126.32,124.66,122.38 × 2,121.32,120.29,115.54 × 2,54.68 × 2,48.44 × 2,45.84.ESI-MS m/z:420.0 (M-H)
-.
Embodiment 12 N
4-(3,5-dimethoxy benzene)-N
2the measurement result of-[4-(4-methylpiperazine-1-yl) benzene]-5-nitro-pyrimidine-2,4-diamines (8) is:
Brown ceramic powder; Productive rate 75.8%; M.p 188.1-190.5 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.304 (1H, s ,-NH), 10.270 (1H, s,-NH), 9.029 (1H, s, H-6), 7.445 (2H, d, J=9.0Hz, H-3 ', H-5 '), 6.783 (2H, d, J=8.4Hz, H-2 ", H-6 "), 6.762 (2H, d, J=8.4Hz, H-2 ', H-6 '), 5.73 (1H, s, H-4 "), 3.668 (6H, s, 3 "-OCH
3, 5 "-OCH
3), 3.070 (4H, s ,-CH
2n (aryl) CH
2-), 2.487 (4H, s ,-CH
2n (CH
3) CH
2-), 2.250 (3H, s ,-NCH
3) .ESI-MS m/z:466.2 (M+H)
+.
Embodiment 13 N
2-[4-(4-methylpiperazine-1-yl) phenyl]-5-nitro-N
4the measurement result of-(3,4,5-trifluorophenyl) pyrimidine-2,4-diamines (9) is:
Brown ceramic powder; Productive rate 80.7%; M.p 256.3-257.2 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.396 (1H, s ,-NH), 10.375 (1H, s ,-NH), 9.073 (1H, s, H-6), 7.680 (2H, d, J=9.0Hz, H-2 ', H-6 '), 7.340 (2H, d, J=9.0Hz, H-3 ', H-5 '), 6.847 (2H, d, J=9.0Hz, H-2 "; H-6 "), 3.109 (4H, s ,-CH
2n (aryl) CH2-), 2.497 (4H, s ,-CH
2n (CH
3) CH
2-), 2.269 (3H, s ,-NCH
3) .ESI-MS m/z:460.1 (M+H)
+.
Embodiment 14 N
4the measurement result of-(4-luorobenzyl)-N2-[4-(4-methylpiperazine-1-yl) benzene]-5-nitro-pyrimidine-2,4-diamines (10) is:
Red powder; Productive rate 78.3%; M.p:221.7-223.5 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.285 (1H, s ,-NH), 9.428 (1H, s ,-NH), 8.967 (1H, s, H-6), 7.557 (2H, d, J=7.8Hz, H-2 ", H-6 "), 7.141 (2H, d, J=9.0Hz, H-3 ", H-5 "), 7.029 (2H, d, J=9.0Hz, H-3 ', H-5 '), 6.912 (2H, d, J=7.8Hz, H-2 ', H-6 '), 4.717 (2H, s ,-CH
2-), 3.477 (4H, s ,-CH
2n (aryl) CH
2-), 3.126 (4H, s ,-CH
2n (CH
3) CH
2-), 2.785 (3H, s ,-NCH
3) .ESI-MS m/z:427.1 (M+H)
+.
Embodiment 15 N-{4-{{2-{ [4-(4-methylpiperazine-1-yl) benzene] amine }-5-nitro-pyrimidine-4-base } amine } benzene } measurement result of acrylamide (11) is:
Red powder; Productive rate 82.6%; M.p > 320 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.571 (1H, s ,-NH), 10.286 (1H, s ,-NH), 10.254 (
1h, s ,-NH), 9.016 (1H, s, H-6), 7.770 (2H, d, J=8.4Hz, H-3 "; H-5 "), 7.430 (2H, d, J=8.4Hz, H-3 ', H-5 '), 7.331 (2H, d, J=8.4Hz, H-2 "; H-6 "), 6.698 (2H, d, J=8.4Hz, H-2 ', H-6 '), 6.586-6.541 (1H, m ,-CH=CH
2), 6.281 (1H, d, J=16.8Hz ,-CH=CH
2), 6.149 (1H, d, J=16.8Hz ,-CH=CH
2), 3.034 (4H, s ,-CH
2n (aryl) CH
2-), 2.408 (4H, s ,-CH
2n (CH
3) CH
2-), 2.206 (3H, s ,-CH
3) .ESI-MS m/z:475.1 (M+H)
+.
Embodiment 16 (Z)-N-{4-{{2-{ [4-(4-methylpiperazine-1-yl) benzene] amine }-5-nitro-pyrimidine-4-base } amine } benzene } measurement result of-3-Phenyl Acrylamide (12) is:
Red powder; Productive rate 84.2%; M.p > 320 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.375 (1H, s ,-NH), 10.292 (1H, s ,-NH), 10.229 (1H, s ,-NH), 9.017 (1H, s, H-6), 7.781 (1H, d, J=8.4Hz,-CH=CH-), 7.684-7.618 (5H, m, C-Ar-H), 7.487-7.406 (8H, m, A, B-H), 7.295 (1H, d, J=8.4Hz ,-CH=CH-), 2.998 (4H, s ,-CH
2n (aryl) CH
2-), 2.325 (4H, s ,-CH
2n (CH
3) CH
2-), 2.027 (3H, s ,-CH
3) .ESI-MS m/z:551.3 (M+H)
+.
The chloro-N-{4-{{2-{ of embodiment 17 4-[4-(4-methylpiperazine-1-yl) benzene] amine }-5-nitro-pyrimidine-4-base } amine } benzene } measurement result of benzamide (13) is:
Red powder, productive rate 66.3%, m.p > 320 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.444 (1H, s,-NH), 10.312 (1H, s,-NH), 10.249 (1H, s,-NH), 9.027 (1H, s, H-6), 8.038 (2H, d, J=8.4Hz, H-2 " ', H-6 " '), 7.830 (2H, d, J=8.4Hz, H-3 " ', H-5 " '), 7.658 (2H, d, J=8.4Hz, H-3 ", H-5 "), 7.468 (2H, d, J=9.0Hz, H-3 ', H-5 '), 7.337 (2H, d, J=9.0Hz, H-2 ", H-6 "), 6.715 (2H, d, J=9.0Hz, H-2 ', H-6 '), 2.992 (4H, s,-CH
2n (aryl) CH
2-), 2.285 (4H, s ,-CH
2n (CH
3) CH
2-), 2.150 (3H, s ,-NCH
3) .ESI-MSm/z:559.1 (M)
+.
The chloro-N-{4-{{2-{ of embodiment 18 3-[4-(methylpiperazine-1-yl) benzene] amine }-5-nitro-pyrimidine-4-base } amine } benzene } measurement result of propionic acid amide (14) is:
Red powder; Productive rate 74.2%; M.p 272.8-273.9 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 10.497 (1H, s ,-NH), 10.298 (1H, s ,-NH), 10.289 (1H, s ,-NH), 9.032 (1H, s, H-6), 7.734 (2H, d, J=8.4Hz, H-3 ", H-5 "), 7.450 (2H, d, J=8.4Hz, H-3 ', H-5 '), 7.387 (2H, d, J=9.0Hz, H-2 "; H-6 "), 6.788 (2H, d, J=9.0Hz, H-2 ', H-6 '), 2.887 (4H, s ,-CH
2n (aryl) CH
2-), 2.728 (4H, s ,-CH
2n (CH
3) CH
2-), 2.653 (3H, s ,-NCH
3), 2.499 (4H, t, J=1.8Hz ,-COCH
2cH
2cl) .ESI-MS m/z:511.0 (M+H)
+.
The chloro-2-{ of embodiment 19 N-{4-{{5-[4-(4-methylpiperazine-1-yl) benzene] amido } pyrimidine-4-yl } amine } phenyl } measurement result of ethanamide (16) is:
White powder; Productive rate 60.3%; M.p 250.9-252.7 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.028 (1H, s ,-NH), 9.009 (1H, s,-NH), 8.683 (1H, s ,-NH), 8.035 (1H, s, H-6), 7.545 (4H, s, H-2 ", H-6 ", H-3 ', H-5 '), 7.403 (2H, d, J=7.8Hz, H-2 ', H-6 '), 6.757 (2H, d, J=7.8Hz, H-3 ", H-5 "), 3.025 (4H, s, CH
2n (aryl) CH2-), 2.454 (4H, s ,-CH
2n (CH
3) CH
2-), 2.222 (3H, s ,-NCH
3), 2.026 (3H, s ,-CH
3) .ESI-MS m/z:452.4 (M+H)
+.
The chloro-2-of the chloro-4-{{5-of embodiment 20 N-{2-[(4-(4-methylpiperazine-1-yl) benzene)] amine } pyrimidine-4-yl } amine } benzene } measurement result of ethanamide (17) is:
White powder; Productive rate 83.5%; M.p:110.5-111.9 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.532 (1H, s ,-NH), 9.135 (1H, s ,-NH), 8.849 (1H, s ,-NH), 8.095 (1H, s, H-6), 7.821 (1H, s, H-2 "); 7.583 (2H, t, J=8.4Hz, H-5 ", H-6 "), 7.404 (2H, d; J=9Hz, H-3 ', H-5 '); 6.821 (2H, d, J=9Hz; H-2 ', H-6 '), 3.033 (4H; t, J=4.8Hz ,-CH
2n (aryl) CH
2-), 2.434 (4H, t, J=4.8Hz ,-CH
2n (CH
3) CH
2-), 2.209 (3H, s ,-NCH
3), 2.088 (3H, s ,-COCH
3) .ESI-MS m/z:486.0 (M)
+.
The chloro-2-{ of embodiment 21 N-{2, the chloro-4-{{5-of 6-bis-[4-(4-methylpiperazine-1-yl) benzene] amine } pyrimidine-4-yl } amine } benzene } measurement result of ethanamide (18) is:
White powder; Productive rate 64.2%; M.p:112.5-114.3 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.679 (1H, s ,-NH), 9.155 (1H, s ,-NH), 8.970 (1H, s ,-NH), 8.106 (1H, s, H-6), 7.950 (1H, s, H-2 "), 7.827 (1H, s; H-6 "), 7.402 (2H, d, J=8.4Hz, H-2 ', H-6 '), 6.839 (2H, d, J=9.0Hz, H-3 ', H-5 '), 3.029 (4H, t, J=4.8Hz ,-CH
2n (aryl) CH
2-), 2.435 (4H, t, J=4.8Hz ,-CH
2n (CH
3) CH
2-), 2.209 (3H, s ,-NCH
3), 2.052 (3H, s ,-CH
3) .ESI-MS m/z:521.2 (M)
+.
The chloro-2-{ of embodiment 22 N-{4-{{5-[4-(4-methylpiperazine-1-yl) benzene] amine } pyrimidine-4-yl } amine }-2-p-methoxy-phenyl } measurement result of ethanamide (19) is:
White powder; Productive rate 66.3%; M.p 113.5-115.9 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.116 (1H, s ,-NH), 9.048 (1H, s ,-NH), 8.701 (1H, s ,-NH), 8.055 (1H, s, H-6), 7.805 (2H, d, J=8.4Hz, H-3 ', H-5 '), 7.414 (2H, d, J=9.0Hz, H-5 "; H-6 "), 7.283 (1H, s, H-2 "), 6.767 (2H, d; J=9.0Hz, H-3 ', H-5 '); 3.718 (3H, s ,-OCH
3), 3.021 (4H, t, J=4.8Hz ,-CH
2n (aryl) CH
2-), 2.438 (4H, t, J=4.8Hz ,-CH
2n (CH
3) CH
2-), 2.212 (3H, s ,-NCH
3), 2.072 (3H, s ,-CH
3) .ESI-MS m/z:482.0 (M+H)
+.
The chloro-2-{ of embodiment 23 N-{4-{{5-[4-(4-methylpiperazine-1-yl) benzene] amine } pyrimidine-4-yl } amine }-2,5-dimethoxy benzenes } measurement result of ethanamide (20) is:
White powder; Productive rate 55.2%; M.p 245.2-247.3 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.200 (1H, s ,-NH), 9.021 (1H, s ,-NH), 8.142 (1H, s, H-6), 8.051 (1H, s, H-3 "), 7.848 (1H; s, H-6 "), 7.498 (1H, s ,-NH), 7.318 (2H, d, J=7.2Hz, H-3 ', H-5 '), 6.739 (2H, d, J=8.4Hz, H-2 ', H-6 '), 3.720 (3H, s, 2 "-OCH
3), 3.632 (3H, s, 5 "-OCH
3), 3.011 (4H, s ,-CH
2n (aryl) CH
2-), 2.435 (4H, s ,-CH
2n (CH
3) CH
2-), 2.214 (3H, s ,-NCH
3), 2.103 (3H, s ,-CH
3) .ESI-MS m/z:512.2 (M)
+.
The chloro-2-of the chloro-4-{{5-of embodiment 24 N-{2-[(2-methoxyl group-4-morpholine phenyl) amine] pyrimidine-4-yl } amine } benzene } measurement result of ethanamide (21) is:
White powder, productive rate 77.5%; M.p:227.2-229.3 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.417 (1H, s ,-NH), 8.770 (1H, s ,-NH), 8.055 (1H, s ,-NH), 7.942 (1H, s, H-6), 7.802 (1H, s, H-2 "); 7.734 (1H, d, J=9.0Hz, H-5 "), 7.666 (1H, d, J=9.0Hz, H-6 "); 7.576 (1H, s, H-3 '), 7.515 (1H; d, J=8.4Hz, H-5 '), 7.444 (1H; d, J=8.4Hz, H-6 '); 3.760 (3H, s ,-OCH
3), 3.741 (4H, t, J=4.8Hz ,-CH
2oCH
2-), 3.087 (4H, t, J=4.8Hz ,-CH
2nCH
2-), 2.075 (3H, s ,-COCH
3) .ESI-MS m/z:503.1 (M+H)
+.
The chloro-2-{ of the chloro-4-{{5-of embodiment 25 N-{2-[2-methoxyl group-4-(4-methylpiperazine-1-yl) benzene] amine } pyrimidine-4-yl } amine } benzene } measurement result of ethanamide (22) is:
Brown ceramic powder; Productive rate 71.5%; Mp:177.3-179.2 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.467 (1H, s ,-NH), (8.777 1H, s ,-NH), 8.052 (1H, s, H-6), 7.935 (1H, s,-NH), 7.808 (1H, s, H-2 "); 7.587 (1H, d, J=8.4Hz, H-5 "), (7.500 1H, d, J=9Hz, H-2 '), (7.424 1H, d, J=9Hz, H-3 '), (6.604 1H, s, H-5 '), 6.442 (1H, d, J=8.4Hz, H-6 "); 3.756 (3H, s ,-OCH
3), 3.144 (4H, s ,-CH
2n (aryl) CH
2-), 2.535 (4H, s ,-CH
2n (CH
3) CH
2-), 2.282 (3H, s ,-NCH
3), 2.076 (3H, s ,-COCH
3) .ESI-MS m/z:516.1 (M)
+.
The chloro-2-{ of embodiment 26 N-{2, the chloro-4-{{5-of 6-bis-[2-methoxyl group-4-(4-methylpiperazine-1-yl) benzene] amine } pyrimidine-4-yl } amine } benzene } measurement result of ethanamide (23) is:
White powder; Productive rate 43.1%; M.p 115.4-116.7 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.668 (1H, s ,-NH), (8.871 1H, s ,-NH), 8.098 (1H, s, H-2 "), 8.088 (1H, s; H-6 "), 7.950 (1H, s,-NH), 7.871 (1H, s, H-6), 7.361 (1H, d, J=8.4Hz, H-2 '), 6.609 (1H, s, H-5 '), 6.458 (1H, d, J=9.0Hz, H-3 '), 3.756 (3H, s ,-OCH
3), 3.117 (4H, s ,-CH
2n (aryl) CH
2-), 2.477 (4H, s ,-CH
2n (CH
3) CH
2-), 2.242 (3H, s ,-NCH
3), 2.044 (3H, s ,-CH
3) .ESI-MS m/z:551.2 (M)
+.
The chloro-2-of embodiment 27 N-{4-{{5-[(2-methoxyl group-4-morpholine benzene) amine] pyrimidine-4-yl } amine }-2-anisole } measurement result of ethanamide (24) is:
White powder; Productive rate 74.7%; M.p 202.3-203.5 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.052 (1H, s ,-NH), (8.642 1H, s ,-NH), 8.026 (1H, s ,-NH), 7.950 (1H, s, H-6), 7.804 (1H, s, H-2 "); 7.762 (1H, d, J=9.0Hz, H-5 "), (7.524 1H, d, J=9.0Hz, H-2 '), (7.804 1H, s, H-5 '), 7.247 (1H, d, J=8.4Hz, H-3 '), 6.386 (1H, d, J=8.4Hz, H-6 "); 3.755 (3H, s ,-OCH
3), 3.741 (4H, t, J=4.8Hz ,-CH
2n (aryl) CH
2-), 3.705 (3H, s ,-OCH
3), 3.077 (4H, t, J=4.8Hz ,-CH
2n (CH
3) CH
2-), 2.068 (3H, s ,-CH
3) .ESI-MS m/z:499.3 (M+H)
+.
The chloro-2-{ of embodiment 28 N-{4-{{5-[2-methoxyl group-4-(4-methylpiperazine-1-yl) benzene] amine } pyrimidine-4-yl } amine }-2-anisole } measurement result of ethanamide (25) is:
White powder; Productive rate 72.5%; Mp:122.3-123.5 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.068 (1H, s ,-NH), (8.644 1H, s ,-NH), 8.019 (1H, s, H-6), 7.780 (1H, s,-NH), 7.753 (1H, d, J=9Hz, H-5 "), 7.500 (1H, d, J=9Hz; H-6 "), 7.314 (1H, s, H-2 "); 7.244 (1H, d, J=8.4Hz, H-2 '); 6.577 (1H, s, H-5 '), 6.366 (1H; d, J=7.2Hz, H-3 '); 3.748 (3H, s ,-OCH
3), 3.696 (3H, s ,-OCH
3), 3.095 (4H, t, J=4.8Hz ,-CH
2n (aryl) CH
2-), 2.449 (4H, t, J=4.8Hz ,-CH
2n (CH
3) CH
2-), 2.221 (3H, s ,-CH
3), 2.064 (3H, s ,-COCH
3) .ESI-MS m/z:512.1 (M)
+.
The chloro-2-of embodiment 29 N-{4-{{5-[(2-methoxyl group-4-morpholine benzene) amine] pyrimidine-4-yl } amine }-2.5-dimethoxy benzene } measurement result of ethanamide (26) is:
Brown ceramic powder; Productive rate 78.6%; M.p:243.7-245.3 DEG C.
1h NMR (600MHz, DMSO-d6): δ (ppm) 9.155 (1H, s ,-NH), 8.082 (1H, s ,-NH), 8.03.7 (1H, s, H-6), 7.950 (1H, s,-NH), 7.831 (1H, s, H-5 "); 7.819 (1H, s, H-5 '), 7.430 (1H; d, J=8.4Hz, H-2 '); 6.587 (1H, d, J=2.4Hz; H-2 "), 6.357 (1H, dd, J=9Hz, J=1.8Hz, H-3 '), 3.749 (3H, s ,-OCH
3), 3.738 (3H, s ,-OCH
3), 3.731 (3H, s ,-OCH
3), 2.888 (4H, s ,-CH
2n (aryl) CH
2-), 2.729 (4H, s ,-CH
2nOCH
2-), 2.089 (3H, s ,-COCH
3) .ESI-MS m/z:429.0 (M)
+.
Above-mentioned detailed description is the illustrating of possible embodiments for invention, and this embodiment is also not used to limit the scope of the claims of the present invention, does not allly depart from equivalence of the present invention and implements or change, and all should be contained in the scope of the claims of the present invention.
In addition, those skilled in the art also can make various amendments in other form and details, interpolation and replacement in the claims in the present invention scope of disclosure and spirit.Certainly, the changes such as these various amendments made according to the present invention's spirit, interpolation and replacement, all should be included within the present invention's scope required for protection.
Claims (9)
1. a class take FGFR as 2,4,5-trisubstituted pyrimidine compounds of target spot, it is characterized in that having following general formula:
Wherein: R
1following arbitrary substituted radical can be selected from:
R
2following arbitrary substituted radical can be selected from:
R
3cl or NO can be selected from
2in any one;
Above R
1, R
2and R
3substituting group can arbitrary combination.
2. prepare the method that a class according to claim 1 take FGFR as 2,4,5-trisubstituted pyrimidine compounds of target spot for one kind, it is characterized in that, comprise the steps:
Step one: take the chloro-5-nitro-pyrimidine of 2,4-bis-, DIPEA and R
1-NH
2in flask, add methylene chloride under stirring and make it dissolve, room temperature reaction, after completion of the reaction, add saturated aqueous common salt, mixture dichloromethane extraction, concentrated, obtain the pulverous 2-R of red solid
1the chloro-5-nitro-pyrimidine of-ammonia-4-;
Step 2: take described 2-R
1-ammonia-4-chloro-5-nitro-pyrimidine and described R
2-NH
2in flask, add sec-butyl alcohol and make it dissolve under stirring, backflow, after reaction terminates, be cooled to room temperature, add sodium bicarbonate neutralization, be extracted with ethyl acetate, concentrated, silica gel column chromatography, eluent is acetate-methanol, obtains 2-R
1-ammonia-4-R
2-ammonia-5-R
3pyrimidine.
3. a kind ofly as claimed in claim 2 prepare the method that a class according to claim 1 take FGFR as 2,4,5-trisubstituted pyrimidine compounds of target spot, it is characterized in that, in described step one, the room temperature reaction time is 5h; 2,4-bis-chloro-5-nitro-pyrimidine methylene dichloride 20ml described in every 1g; The chloro-5-nitro-pyrimidine of the ratio of amount of substance: 2,4-bis-: DIPEA: R
1-NH
2=1:1:1.
4. a kind ofly as claimed in claim 2 prepare the method that a class according to claim 1 take FGFR as 2,4,5-trisubstituted pyrimidine compounds of target spot, it is characterized in that, in described step 2,2-R described in every 500mg
1-ammonia-4-chloro-5-nitro-pyrimidine sec-butyl alcohol 15-20ml dissolves, then instills in flask by trifluoroacetic acid, the ratio of amount of substance: 2-R
1the chloro-5-R of-ammonia-4-
3pyrimidine: R
2-NH
2: trifluoroacetic acid=1:1:1; Described return time is 2h, and described extraction times is 3 times, and described eluent is acetate-methanol, and the volume ratio of ethyl acetate and methyl alcohol is 20:1.
5. prepare the method that a class according to claim 1 take FGFR as 2,4,5-trisubstituted pyrimidine compounds of target spot for one kind, it is characterized in that, comprise the steps:
Step one: take 2,4,5-trichloropyrimidine, Anhydrous potassium carbonate and described R
1-NH
2in flask, stirring adds DMF makes it dissolve, and 60 DEG C of reaction 2-3h, after completion of the reaction, are cooled to room temperature, add a large amount of frozen water, have solid to separate out, suction filtration, dry, obtain 2-R
1-ammonia-4,5-dichloro pyrimidine;
Step 2: take described 2-R
1-ammonia-4-chloro-5-dichloro pyrimidine and described R
2-NH
2in flask, add described sec-butyl alcohol and make it dissolve under stirring, backflow, after reaction terminates, be cooled to room temperature, add sodium bicarbonate neutralization, be extracted with ethyl acetate, concentrated, silica gel column chromatography, eluent is acetate-methanol, obtains 2-R
1-ammonia-4-R
2-ammonia-5-R
3pyrimidine.
6. an a kind of class of preparing take FGFR as 2 of target spot as claimed in claim 5,4, the method of 5-trisubstituted pyrimidine compounds, it is characterized in that, in described step one: every 1g 2,4,5-trichloropyrimidine DMF 5-10ml dissolves, the ratio of amount of substance: 2,4,5-trichloropyrimidine: Anhydrous potassium carbonate: R
1-NH
2=1:2:1; In described step 2: 2-R described in every 500mg
1-ammonia-4-chloro-5-dichloro pyrimidine sec-butyl alcohol 15-20ml, then trifluoroacetic acid is instilled in flask, the ratio of amount of substance: 2-R
1the chloro-5-dichloro pyrimidine of-ammonia-4-: R
2-NH
2: trifluoroacetic acid=1:1:1, described return time is 2h, and described extraction times is 3 times, and the volume ratio of described eluant ethyl acetate and methyl alcohol is 20:1.
7. a class take FGFR as the purposes of 2,4,5-trisubstituted pyrimidine compounds of target spot, it is characterized in that, described purposes is the application prepared in antitumor drug.
8. a pharmaceutical composition, is characterized in that, comprises 2,4, the 5-trisubstituted pyrimidine compounds that pharmaceutical excipient and a class as claimed in claim 1 take FGFR as target spot.
9. the class that contains according to claim 8 take FGFR as 2 of target spot, 4, the pharmaceutical composition of 5-trisubstituted pyrimidine compounds, it is characterized in that, the dosage form of described pharmaceutical composition is any one of injection, tablet, capsule, aerosol, suppository, film, pill, ointment, control-released agent, sustained release dosage or nanometer formulation.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510180883.3A CN104803925B (en) | 2015-04-16 | 2015-04-16 | A kind of 2,4,5 trisubstituted pyrimidine class compounds using FGFR as target spot and its production and use |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510180883.3A CN104803925B (en) | 2015-04-16 | 2015-04-16 | A kind of 2,4,5 trisubstituted pyrimidine class compounds using FGFR as target spot and its production and use |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104803925A true CN104803925A (en) | 2015-07-29 |
CN104803925B CN104803925B (en) | 2018-01-12 |
Family
ID=53689164
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510180883.3A Expired - Fee Related CN104803925B (en) | 2015-04-16 | 2015-04-16 | A kind of 2,4,5 trisubstituted pyrimidine class compounds using FGFR as target spot and its production and use |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104803925B (en) |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105017160A (en) * | 2015-06-24 | 2015-11-04 | 温州医科大学 | Pyrimidine EGFRT790M inhibitors and their synthesis method and use |
CN106831730A (en) * | 2017-01-11 | 2017-06-13 | 温州医科大学 | A kind of substituted diaminopyrimidines and its purposes in anti-malignant tumor medicine is prepared |
WO2018019204A1 (en) * | 2016-07-26 | 2018-02-01 | 深圳市塔吉瑞生物医药有限公司 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity |
CN110746402A (en) * | 2019-09-21 | 2020-02-04 | 温州医科大学 | 2-N-aryl-4-N-aryl-5-fluoropyrimidine compound and preparation method and application thereof |
CN111777592A (en) * | 2020-06-22 | 2020-10-16 | 温州医科大学 | N4- (2, 5-dimethoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof |
CN111793035A (en) * | 2020-06-22 | 2020-10-20 | 温州医科大学 | N4- (3-methoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof |
CN113956234A (en) * | 2021-10-27 | 2022-01-21 | 温州医科大学 | N-phenyl substituted 1H-indazole-3-amine compound, preparation thereof and application thereof in antitumor activity |
CN115141181A (en) * | 2022-06-14 | 2022-10-04 | 温州医科大学 | Novel small molecule compound and preparation method and application thereof |
CN115477639A (en) * | 2022-08-26 | 2022-12-16 | 温州医科大学 | Multi-substituted pyrimidine compound with FGFR1 as target spot, and preparation method and application thereof |
CN115894381A (en) * | 2022-11-11 | 2023-04-04 | 温州医科大学 | 2,4,5-trisubstituted pyrimidine compound and preparation method and application thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101006079A (en) * | 2004-08-27 | 2007-07-25 | 诺瓦提斯公司 | Pyrimidine derivatives |
CN101336237A (en) * | 2005-12-21 | 2008-12-31 | 诺瓦提斯公司 | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
WO2009101199A2 (en) * | 2008-02-15 | 2009-08-20 | Bodo Melnik | Treatment of acne vulgaris; rosacea and rhinophym |
CN102459236A (en) * | 2009-05-27 | 2012-05-16 | 雅培制药有限公司 | Pyrimidine inhibitors of kinase activity |
CN102639510A (en) * | 2009-12-07 | 2012-08-15 | 诺瓦提斯公司 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
WO2014079709A1 (en) * | 2012-11-23 | 2014-05-30 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
WO2015003658A1 (en) * | 2013-07-11 | 2015-01-15 | Betta Pharmaceuticals Co., Ltd | Protein tyrosine kinase modulators and methods of use |
-
2015
- 2015-04-16 CN CN201510180883.3A patent/CN104803925B/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101006079A (en) * | 2004-08-27 | 2007-07-25 | 诺瓦提斯公司 | Pyrimidine derivatives |
CN101336237A (en) * | 2005-12-21 | 2008-12-31 | 诺瓦提斯公司 | Pyrimidinyl aryl urea derivatives being fgf inhibitors |
WO2009101199A2 (en) * | 2008-02-15 | 2009-08-20 | Bodo Melnik | Treatment of acne vulgaris; rosacea and rhinophym |
CN102459236A (en) * | 2009-05-27 | 2012-05-16 | 雅培制药有限公司 | Pyrimidine inhibitors of kinase activity |
CN102639510A (en) * | 2009-12-07 | 2012-08-15 | 诺瓦提斯公司 | Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof |
WO2014079709A1 (en) * | 2012-11-23 | 2014-05-30 | Ab Science | Use of small molecule inhibitors/activators in combination with (deoxy)nucleoside or (deoxy)nucleotide analogs for treatment of cancer and hematological malignancies or viral infections |
WO2015003658A1 (en) * | 2013-07-11 | 2015-01-15 | Betta Pharmaceuticals Co., Ltd | Protein tyrosine kinase modulators and methods of use |
Non-Patent Citations (5)
Title |
---|
CHI HOON PARK,等: "Novel bis-ortho-alkoxy-para-piperazinesubstituted-2,4-dianilinopyrimidines (KRCA-0008) as potent and selective ALK inhibitors for anticancer treatment", 《BIOORGANIC & MEDICINAL CHEMISTRY LETTERS》 * |
LUXI ZHANG,等: "Characterization of the Novel Broad-Spectrum Kinase Inhibitor CTx-0294885 As an Affinity Reagent for Mass Spectrometry-Based Kinome Profiling", 《JOURNAL OF PROTEOME RESEARCH》 * |
QI-ZHENG SUN,等: "Structural modification of an EGFR inhibitor that showed weak off-target activity against RET leading to the discovery of a potent RET inhibitor", 《MOLECULAR DIVERSITY》 * |
WEI ZHOU,等: "Discovery of Pteridin-7(8H)-one-Based Irreversible Inhibitors Targeting the Epidermal Growth Factor Receptor (EGFR) Kinase T790M/L858R Mutant", 《JOURNAL OF MEDICINAL CHEMISTRY》 * |
张颖,等: "FGFR抗体类肿瘤药物的研发现状及发展趋势", 《生物产业技术》 * |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105017160A (en) * | 2015-06-24 | 2015-11-04 | 温州医科大学 | Pyrimidine EGFRT790M inhibitors and their synthesis method and use |
WO2018019204A1 (en) * | 2016-07-26 | 2018-02-01 | 深圳市塔吉瑞生物医药有限公司 | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity |
CN108602802A (en) * | 2016-07-26 | 2018-09-28 | 深圳市塔吉瑞生物医药有限公司 | Amino-metadiazine compound for inhibiting protein tyrosine kinase activity |
CN108602802B (en) * | 2016-07-26 | 2020-01-21 | 深圳市塔吉瑞生物医药有限公司 | Aminopyrimidines useful for inhibiting protein tyrosine kinase activity |
US11111233B2 (en) | 2016-07-26 | 2021-09-07 | Shenzhen Targetrx, Inc. | Amino pyrimidine compound for inhibiting protein tyrosine kinase activity |
CN106831730A (en) * | 2017-01-11 | 2017-06-13 | 温州医科大学 | A kind of substituted diaminopyrimidines and its purposes in anti-malignant tumor medicine is prepared |
CN110746402A (en) * | 2019-09-21 | 2020-02-04 | 温州医科大学 | 2-N-aryl-4-N-aryl-5-fluoropyrimidine compound and preparation method and application thereof |
CN111777592B (en) * | 2020-06-22 | 2021-06-18 | 温州医科大学 | N4- (2, 5-dimethoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof |
CN111793035A (en) * | 2020-06-22 | 2020-10-20 | 温州医科大学 | N4- (3-methoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof |
CN111793035B (en) * | 2020-06-22 | 2021-06-18 | 温州医科大学 | N4- (3-methoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof |
CN111777592A (en) * | 2020-06-22 | 2020-10-16 | 温州医科大学 | N4- (2, 5-dimethoxyphenyl) -pyrimidinediamine targeted DDR1 inhibitor and preparation and application thereof |
CN113956234A (en) * | 2021-10-27 | 2022-01-21 | 温州医科大学 | N-phenyl substituted 1H-indazole-3-amine compound, preparation thereof and application thereof in antitumor activity |
CN115141181A (en) * | 2022-06-14 | 2022-10-04 | 温州医科大学 | Novel small molecule compound and preparation method and application thereof |
CN115477639A (en) * | 2022-08-26 | 2022-12-16 | 温州医科大学 | Multi-substituted pyrimidine compound with FGFR1 as target spot, and preparation method and application thereof |
CN115477639B (en) * | 2022-08-26 | 2023-11-03 | 温州医科大学 | Polysubstituted pyrimidine compound with FGFR1 as target point, and preparation method and application thereof |
CN115894381A (en) * | 2022-11-11 | 2023-04-04 | 温州医科大学 | 2,4,5-trisubstituted pyrimidine compound and preparation method and application thereof |
Also Published As
Publication number | Publication date |
---|---|
CN104803925B (en) | 2018-01-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104803925A (en) | 2,4,5-trisubstituted pyrimidine compounds taking FGFRs (fibroblast growth factor receptors) as targets as well as preparation methods and application of 2,4,5-trisubstituted pyrimidine compounds | |
AU2018271284B2 (en) | Pyrimidine FGFR4 inhibitors | |
Liu et al. | Design, synthesis and biological evaluation of novel thieno [3, 2-d] pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents | |
CA2542076C (en) | Substituted tricyclic compounds as protein kinase inhibitors | |
CN101166732B (en) | Cyanopyridine derivative and use thereof as medicine | |
CN1807413B (en) | Carbazole sulfonamide derivative and its preparation method | |
CN103965120A (en) | Quinoline and quinazoline derivative, preparation method, intermediate, composition and application | |
KR20110099332A (en) | Preparation method of dihydroindene amide compounds, their pharmaceutical compositions containg compounds thereof and use as protein kinases inhibitor | |
CA2679489A1 (en) | Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors | |
CN112204010B (en) | Heterocyclic derivatives and uses thereof | |
Tu et al. | Design, synthesis, and docking studies of afatinib analogs bearing cinnamamide moiety as potent EGFR inhibitors | |
KR102214225B1 (en) | 5-membered heterocyclic amide type WNT pathway inhibitor | |
Zhang et al. | Discovery of novel anti-angiogenesis agents. Part 6: Multi-targeted RTK inhibitors | |
Shan et al. | Expanding the structural diversity of diarylureas as multi-target tyrosine kinase inhibitors | |
BR112019027292A2 (en) | coumarin-like cyclic compound as a mek inhibitor and use of it | |
CN103739550B (en) | 2,3-dimethyl-6-urea-2H-indazole compounds and its preparation method and application | |
CN103450176A (en) | Naphthalimide compound containing 2-(4-aminophenyl) benzothiazole and application thereof | |
CN107383014B (en) | A kind of 1H- pyrazolo [3,4-d] pyrimidines and its preparation method and application | |
CN103382182B (en) | Phenylurea coupling quinazoline compounds and preparation method thereof, pharmaceutical composition and medicinal usage | |
CN108329274A (en) | Bruton's tyrosine kinase inhibitor | |
CN106349224A (en) | JAK kinase inhibitor with 4-amino-(1H)-pyrazole structure and preparation method and application thereof | |
CN113956234B (en) | N-phenyl substituted 1H-indazole-3-amine compound, preparation thereof and application of antitumor activity | |
CN106866642B (en) | Quinazoline compound containing aryl acylhydrazone structure and application thereof | |
CN102234270A (en) | Diarylurea derivatives and treatment application thereof | |
CN106496232B (en) | A kind of 1- with anti-tumor activity (2- oxinanes) -1H- pyrazolos [3,4-d] pyrimidines and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180112 |